PRPF31 and retinitis pigmentosa 1: Researchers have begun preparatory work to define pre-treatment characteristics of RP associated with PRPF31 mutations in order to be able to assess the effectiveness of AAV-mediated PRPF31 gene augmentation therapy(Hafler et al., 2016).